Article
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Internal medicine (Tokyo, Japan) - 1 Sept 2017
Akiyama Norimichi, Karayama Masato, Iwaizumi Moriya, Kusama Yukiko, Kono Masato, Hozumi Hironao, Suzuki Yuzo, Furuhashi Kazuki, Enomoto Noriyuki, Fujisawa Tomoyuki, Nakamura Yutaro, Inui Naoki, Suda Takafumi
Abstract excerpt
Chemotherapy for multiple primary cancers is challenging. We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. A 78-year-old woman with advanced EGFR-mutated lung adenocarcinoma was simultaneously diagnosed with duodenal adenocarcinoma. After the treatment with erlotinib, the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.